Indeed, in DESTINY-Breast01 clinical trial enrolling 184 female patients with unresectable or metastatic HER2-positive breast cancer who had received two or more prior anti-HER2-based regimens, T-DXd (5.4 mg/kg dose) showed favorable and durable anti-tumor activity4. Here, ERBB2 is linked to breast carcinoma.